SPONSOR
Shandong Cancer Hospital and Institute
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 2, Phase 1, Phase 2
Conditions studied: Head & Neck Squamous Cell CarcinomaHead & Neck CancerOligoProgressive Metastatic DiseaseHepatocellular Carcinoma (HCC)RadiotherapySystemic TherapyPancreas CancerTo Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients
Shandong Cancer Hospital and Institute is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC).
The trial portfolio spans Phase 3, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shandong Cancer Hospital and Institute
How many clinical trials has Shandong Cancer Hospital and Institute sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Shandong Cancer Hospital and Institute, of which 4 are actively recruiting participants. These trials cover conditions including Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, OligoProgressive Metastatic Disease. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shandong Cancer Hospital and Institute research focus on?
Shandong Cancer Hospital and Institute clinical trials span Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC), Radiotherapy, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shandong Cancer Hospital and Institute clinical trial?
To participate in a Shandong Cancer Hospital and Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shandong Cancer Hospital and Institute trials with current recruitment status updated daily.
Clinical Trials by Shandong Cancer Hospital and Institute
NCT07333274 Phase 3
Recruiting
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Head & Neck Squamous Cell Carcinoma
NCT06841172 Phase 3
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
OligoProgressive Metastatic Disease
NCT06050317 Phase 2
Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Pancreas Cancer
NCT06847555 Phase 1, Phase 2
Recruiting
Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology